THYAS
Thyas Co. Ltd. provides preparations of regenerative immunocell therapy for cancer and infection.
THYAS
Social Links:
Industry:
Health Care Medical Therapeutics
Founded:
2015-08-01
Address:
Kyoto, Kyoto, Japan
Country:
Japan
Website Url:
http://www.thyas.co.jp
Total Employee:
1+
Status:
Active
Total Funding:
539 M JPY
Technology used in webpage:
SPF Person Schema Gravatar Profiles GMO Internet
Similar Organizations
4SaveU
Early detection of breast cancer by memogrephy image processing.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Gracell Biotechnologies
Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer.
Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
Slingshot Biosciences
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Verismo Therapeutics
Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer.
Current Advisors List
Current Employees Featured
Founder
Investors List
Future Venture Capital
Future Venture Capital investment in Venture Round - Thyas
Kyoto University Innovation Capital
Kyoto University Innovation Capital investment in Venture Round - Thyas
Chuo Shinkin Venture Capital
Chuo Shinkin Venture Capital investment in Venture Round - Thyas
SMBC Venture Capital
SMBC Venture Capital investment in Venture Round - Thyas
Kyoto University Innovation Capital
Kyoto University Innovation Capital investment in Venture Round - Thyas
Kyoto University Innovation Capital
Kyoto University Innovation Capital investment in Venture Round - Thyas
Kyoto University Innovation Capital
Kyoto University Innovation Capital investment in Venture Round - Thyas
Official Site Inspections
http://www.thyas.co.jp
- Host name: www10.gmoserver.jp
- IP address: 160.251.229.16
- Location: Tokyo Japan
- Latitude: 35.6882
- Longitude: 139.7532
- Timezone: Asia/Tokyo
- Postal: 102-0082
More informations about "Thyas"
サイアス株式会社オフィシャルウェブサイトはリニューアルしま …
サイアス株式会社オフィシャル ウェブサイトはリニューアルしました 当社は2023年1月に米国 Thyas Inc.を100%親会社とする組織再編を実施し、グローバル・カンパニーとして、低免疫 …See details»
Thyas enters into joint research agreement and exclusive license …
Dec 20, 2022 Thyas Co. Ltd. ("Thyas"; Kyoto, Japan; Representative Directors, Yasumichi Hitoshi and Ryosuke Gonotsubo) has announced it concluded a joint research agreement and …See details»
Thyas Co. Ltd. - LinkedIn
Thyas Co. Ltd. Biotechnology Research Kyoto, Kyoto 144 followers We Regenerate Your Immune System.See details»
サイアス株式会社が三角株式交換により米国サイアス・インクを …
Feb 14, 2023 サイアス株式会社（京都市左京区、代表取締役 等泰道、五ノ坪良輔） は、米国サイアス・インク（Thyas Inc. 米デラウェア州、共同CEO 等泰道）を ...See details»
サイアス株式会社（京都企業紹介）Thyas Co., Ltd.／京都府ホーム …
サイアス株式会社（京都企業紹介）Thyas Co., Ltd. 知恵の経営、元気印、経営革新、チャレンジ・バイの各認定等を受けた府内中小企業を紹介するページです。See details»
Thyas - Crunchbase Company Profile & Funding
Thyas closed its last funding round on Nov 20, 2019 from a Venture - Series Unknown round. Who are Thyas 's competitors? Alternatives and possible competitors to Thyas may include …See details»
Thyas Co. Ltd., a Kyoto University spin-off, Closes JPY 2.1B Series B ...
About Thyas Co. Ltd. Founded in 2015, Thyas is a Kyoto University spinoff that promotes R&D for the clinical application of iPS cell-derived immune cells based on the researches by Dr. Shin …See details»
Scientist, Cell manufacturing, - Thyas
At Thyas, we are aiming to deliver curative cell-based immunotherapies to patients with cancers and other deadly diseases. Thyas has innovative science originating from Dr. Shin Kaneko, …See details»
再生医療ベンチャー#47 サイアス | 再生医療.net
Dec 25, 2019 Thyas Co. Ltd. 所在地 京都市左京区吉田下阿達町46-29 京都大学医薬系総合研究棟411, 413S, 415 : 代表者 代表取締役 等 泰道 設立 2015年8月24日 上場 非上場 【会社概要 …See details»
Message by Thyas Co., Ltd. | P.S. i LOVE YOU PROJECT
With this in mind, Thyas is working hard. About the organization Thyas was established based on the research of CiRA Professor Shin Kaneko, who is world’s leading scientist to develop …See details»
Thyas 2025 Company Profile: Valuation, Funding & Investors
Www.thyas.co.jp. Ownership Status. Privately Held (backing) Financing Status. Venture Capital-Backed. Corporate Office. 46-29 Yoshidashimoadachi Sakyo-ku; University Med-Pharm …See details»
Thyas Co., Ltd. | | Healthcare Venture Conference KYOTO | 京都リ …
Nov 4, 2022 Yasumichi Hitoshi, M.D., CEO, Thyas Co., Ltd. Profile. Yasumichi Hitoshi is CEO at Thyas Co. Ltd, Kyoto (2017~), where he directs R&D activities for adoptive immunotherapy …See details»
Thyas Co. Ltd. Overview | SignalHire Company Profile
Organization Website: thyas.co.jp : Phone Number +81-75-752-1555: Thyas Co. Ltd. industries Biotech: Headquarters Location: 46-29 Yoshida-Shimo-Adachi-Cho, Sakyo-ku,, Kyoto, …See details»
Thyas - Products, Competitors, Financials, Employees, …
Email: [email protected] Thyas Co. Ltd., a Kyoto University spin-off, Closes JPY 2.1B Series B Financing from Eight Roads Ventures/F-Prime to Develop Novel iPSC-derived Immune Cell …See details»
Thyas Co., Ltd. - VentureRadar
Website: https://thyas.co.jp/ Develops innovative cell therapeutics for cancer treatment using T-iPSC technology, focusing on personalized medicine and immunotherapy advancements. ...See details»
Basic agreement with Thyas for the manufacturing of iPS cell …
Kyoto, Japan, 1 February 2021 - The CiRA FoundationR (CiRA_F) today has signed the following two agreements with Thyas Co. Ltd. ("Thyas"; located in Sakyo-ku, Kyoto) (1) Basic …See details»
Ki-CONNECT has agreed and signed a contract with Thyas Co. Ltd.
Nov 20, 2020 Thyas Co., Ltd. is a startup Biotech company, developing cancer immunotherapy using rejuvenated iPSC-derived T cells (iPS-T) for the treatment of solid tumors. Its …See details»
シノビ・セラピューティクス株式会社の企業情報 | FUMA（フー …
サイアス（英名：ThyasCo.Ltd.）は、2015年設立。京都大学発の医学研究所である。ヒトiPS細胞から免疫細胞を再生し、がんや感染症に対する個別化された再生免疫細胞療法の提供を目 …See details»
Press Release - thyas.co.jp
Basic agreement with Thyas Co. Ltd. for the manufacturing of iPS cell-derived T cells ... Email: PR -g@cira foundation.or.jp Inquiries about the consignment and research: Management …See details»
AMED to Provide Thyas $7.2 Million (JPY 950 Million ... - thyas.co.jp
Dec 28, 2022 Thyas aims to make the immune cell therapy curative for solid tumors and accesible for many cancer patients in the world. <About Thyas> Founded in 2015, Thyas is a …See details»